Drug intelligence / Profile preview

placebo + escitalopram

Development stage
Unknown
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral
01

Overview

This combination intervention refers to a specific control arm used in clinical research conducted by the Milton S. Hershey Medical Center, notably in the trial NCT00746239. The intervention consists of the selective serotonin reuptake inhibitor (SSRI) escitalopram administered alongside a placebo. In the context of the study, this arm served as the comparator to evaluate the efficacy of adding ramelteon to standard escitalopram treatment for patients with panic disorder and comorbid sleep initiation insomnia. Escitalopram is a small molecule antidepressant and anxiolytic that primarily targets the serotonin transporter (SERT), inhibiting the reuptake of serotonin into the presynaptic neuron and thereby increasing synaptic serotonin levels. In this trial, escitalopram was used to manage the underlying anxiety and panic symptoms, while the placebo replaced the investigational sleep aid to determine its incremental benefit on sleep quality.

Brand names
Lexapro
Other names
escitalopram + placebo
02

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on placebo + escitalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on placebo + escitalopram.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call